Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227690 · ClinicalTrials.gov registry record · Phase 2
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
A Phase 2 study of Schizophrenia, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
- 20
- Study locations
NCT05227690 is a Phase 2 study of Schizophrenia that has completed, run by AbbVie. The registered enrollment target is 385 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (77% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT05227690, a Phase 2 study of Schizophrenia, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Emraclidine 10 mg
- DRUG Emraclidine 30 mg
Study Locations (20)
California
- Anaheim, California - Anaheim
- Garden Grove, California - Garden Grove
- Lemon Grove, California - Lemon Grove
- Montclair, California - Montclair
- Riverside, California - Riverside
- San Diego, California - San Diego
Florida
- Hialeah, Florida - Hialeah
- Hollywood, Florida - Hollywood
- Mangonia Park, Florida - Mangonia Park
- Oakland Park, Florida - Oakland Park
Texas
- DeSoto, Texas - DeSoto
- Houston, Texas - Houston
- Irving, Texas - Irving
Georgia
- Atlanta, Georgia - Atlanta
- Decatur, Georgia - Decatur
Arkansas
- Little Rock, Arkansas - Little Rock
Louisiana
- Shreveport, Louisiana - Shreveport
Maryland
- Gaithersburg, Maryland - Gaithersburg
Mississippi
- Flowood, Mississippi - Flowood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2022-06-30 |
| Est. Completion | 2024-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05227690
The ClinicalTrials.gov registry entry for NCT05227690 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (77% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05227690 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT05227690 about?
NCT05227690 is a clinical study titled "A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia". This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing ...
What is the current status of trial NCT05227690?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2022-06-30. Estimated completion is 2024-08-26.
What conditions does trial NCT05227690 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT05227690?
The interventions under investigation include: Placebo (DRUG), Emraclidine 10 mg (DRUG), Emraclidine 30 mg (DRUG).
Who is sponsoring clinical trial NCT05227690?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05227690 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.